ReviewNeuro-oncology2019
The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients.
Review in Neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Metabolic Imaging as Future Technology and Innovation in Brain-Tumour Surgery: A Systematic Review.Current oncology (Toronto, Ont.) · 2025Pooled it
- Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2.International journal of clinical oncology · 2024Guideline
- Application of radiomics to meningiomas: A systematic review.Neuro-oncology · 2023Pooled it
- Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of cytotoxic chemotherapy and other cytotoxic therapies in the management of progressive glioblastoma in adults.Journal of neuro-oncology · 2022Guideline
- CSF ctDNA analysis guides molecular reclassification of diffuse glioma patients.Journal of neuro-oncology · 2026Article
- Impact of an evolving classification system on diffuse glioma repositories: experience from the Sydney brain tumour bank.Journal of neuro-oncology · 2026Article
- Global, regional, and national burden of brain and other central nervous system cancers from 1990 to 2021, and projections to 2035: a systematic analysis for the global burden of disease study 2021.International journal of surgery (London, England) · 2026Article
- Real-Time Detection of Meningiomas by Image Segmentation: A Very Deep Transfer Learning Convolutional Neural Network Approach.Tomography (Ann Arbor, Mich.) · 2025Article
- Characterizing the Natural History of Pediatric Brain Tumors Presenting with Metastasis.Cancers · 2025Article
- Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology Consensus Review on diagnosis, management, and future directions.Neuro-oncology · 2025Review
- Review
- Diagnostic challenges in complicated case of glioblastoma.Pathology oncology research : POR · 2024Article
- Building Team Medicine in the Management of CNS Metastases.Journal of clinical medicine · 2023Article
- From Theory to Practice: Implementing the WHO 2021 Classification of Adult Diffuse Gliomas in Neuropathology Diagnosis.Brain sciences · 2023Review
- An expedited strategy for accurate and timely integrated molecular diagnosis of gliomas.Neuro-oncology · 2023Article
- Evaluation of Two Post-Processing Analysis Methods of Proton Magnetic Resonance Spectroscopy in Glioma Tumors.Journal of biomedical physics & engineering · 2023Article
- Events in CNS Tumor Pathology Post-2016 WHO CNS: cIMPACT-NOW Updates and Other Advancements: A Comprehensive Review Plus a Summary of the Salient Features of 2021 WHO CNS 5.International journal of general medicine · 2023Review
- Toward a More Just System of Care in Molecular Pathology.The Milbank quarterly · 2022Article
- Neuro-oncology at the American Society for Clinical Oncology 2022 Annual Meeting.Neuro-oncology practice · 2022Article
- Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States.Neuro-oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Accurate pathologic diagnoses and molecularly informed treatment decisions for a wide variety of cancers depend on robust clinical molecular testing that uses genomic, epigenomic, and transcriptomic-based tools. Nowhere is this more essential than in the workup of brain tumors, as emphasized by the incorporation of molecular criteria into the 2016 World Health Organization classification of central nervous system tumors and the updated official guidelines of the National Comprehensive Cancer Network. Despite the medical necessity of molecular testing in brain tumors, access to and utilization of molecular diagnostics is still highly variable across institutions, and a lack of reimbursement for such testing remains a significant obstacle. The objectives of this review are (i) to identify barriers to adoption of molecular testing in brain tumors, (ii) to describe the current molecular tools recommended for the clinical evaluation of brain tumors, and (iii) to summarize how molecular data are interpreted to guide clinical care, so as to improve understanding and justification for their coverage in the routine workup of adult and pediatric brain tumor cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.